MedTrace Logo

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

NCT02858908 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-09-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy. The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.

Conditions

  • Myotonic Dystrophy 1

Interventions

DRUG

Tideglusib

Tideglusib for oral suspension,

Sponsors & Collaborators

  • AMO Pharma Limited

    lead INDUSTRY

Principal Investigators

  • Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP · Institute of Neuroscience, Newcastle University.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-20
Primary Completion
2018-01-31
Completion
2018-01-31
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02858908 on ClinicalTrials.gov